Testing glenzocimab for large stroke after clot removal
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests a new medicine (glenzocimab) given along with standard clot-removal procedure for people who had a stroke with a large area of brain damage. The goal is to see if the medicine helps improve recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a stroke caused by a blockage in a large artery in the front of your brain (M1, M2, or terminal internal carotid artery)
- You are eligible for a clot-removal procedure within 24 hours of your stroke starting
- Your brain scan shows a large area of damage (ASPECTS less than 6)
- You do not have significant disability before this stroke (able to do most daily activities on your own)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medicine (a GLP-1 receptor agonist) given along with the standard clot-removal procedure for people who have had a severe stroke from a large blockage. The goal is to see if the medicine helps improve recovery by protecting the brain.
This trial tests if removing a large blood clot from the brain up to 3 days after a stroke improves recovery compared to standard medical care alone. It is for patients who have a severe stroke and are otherwise healthy enough for the procedure.
This Phase 2 trial tests whether the study medicine (LT3001) is safe and improves outcomes for people with an acute ischemic stroke who are getting a procedure to remove a clot (EVT). It aims to help certain patients who have a specific brain scan pattern soon after stroke symptoms start.
This trial tests giving a clot-dissolving medicine (rhPro-UK) through a vein before a procedure to remove a large blood clot in the brain. It is for people who had a stroke 4.5 to 24 hours ago and are already scheduled for clot removal. The goal is to see if the medicine helps improve blood flow and outcomes.
This trial tests a clot-dissolving drug called tenecteplase given 4.5 to 24 hours after a stroke caused by a blockage in a medium-sized brain artery. It aims to see if waiting longer than usual still helps reduce disability.
This study tests whether adding a drug called human urinary kallidinogenase to standard clot-removal therapy helps people recover better after a large-vessel stroke. If you qualify, you would receive the drug or a placebo by IV along with the procedure, and doctors will monitor your recovery.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.